BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25808869)

  • 1. Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction.
    Zhang S; Chung WC; Wu G; Egan SE; Miele L; Xu K
    Cancer Res; 2015 May; 75(10):1936-43. PubMed ID: 25808869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.
    Chung WC; Zhang S; Challagundla L; Zhou Y; Xu K
    Neoplasia; 2017 Nov; 19(11):885-895. PubMed ID: 28938159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galactose differentially modulates lunatic and manic fringe effects on Delta1-induced NOTCH signaling.
    Hou X; Tashima Y; Stanley P
    J Biol Chem; 2012 Jan; 287(1):474-483. PubMed ID: 22081605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.
    Xu K; Usary J; Kousis PC; Prat A; Wang DY; Adams JR; Wang W; Loch AJ; Deng T; Zhao W; Cardiff RD; Yoon K; Gaiano N; Ling V; Beyene J; Zacksenhaus E; Gridley T; Leong WL; Guidos CJ; Perou CM; Egan SE
    Cancer Cell; 2012 May; 21(5):626-641. PubMed ID: 22624713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.
    Majumder M; Xin X; Liu L; Tutunea-Fatan E; Rodriguez-Torres M; Vincent K; Postovit LM; Hess D; Lala PK
    Stem Cells; 2016 Sep; 34(9):2290-305. PubMed ID: 27301070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
    Zhang S; Chung WC; Miele L; Xu K
    Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer.
    Chang J; Hong L; Liu Y; Pan Y; Yang H; Ye W; Xu K; Li Z; Zhang S
    Cancer Manag Res; 2020; 12():2641-2651. PubMed ID: 32368142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic and prognosis features of Claudin-low breast cancers].
    Xu J; Lan KT; Su TH; Li ZF; Wan Y; Gu QQ; Zou PC; Zou X
    Zhonghua Bing Li Xue Za Zhi; 2017 Sep; 46(9):634-639. PubMed ID: 28910875
    [No Abstract]   [Full Text] [Related]  

  • 9. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.
    Colavito SA; Zou MR; Yan Q; Nguyen DX; Stern DF
    Breast Cancer Res; 2014 Sep; 16(5):444. PubMed ID: 25252859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear and stromal expression of Manic fringe in renal cell carcinoma.
    Cheng WK; Kaur G; Sjöberg E; Frödin M; Egevad L; Harmenberg U; Li JL; Oon CE
    Exp Mol Pathol; 2021 Oct; 122():104667. PubMed ID: 34371013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion.
    Xie Y; Abel PW; Kirui JK; Deng C; Sharma P; Wolff DW; Toews ML; Tu Y
    Biochem Pharmacol; 2013 May; 85(10):1454-62. PubMed ID: 23500535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch activation stimulates migration of breast cancer cells and promotes tumor growth.
    Bolós V; Mira E; Martínez-Poveda B; Luxán G; Cañamero M; Martínez-A C; Mañes S; de la Pompa JL
    Breast Cancer Res; 2013; 15(4):R54. PubMed ID: 23826634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
    Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
    Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.
    Knezevic J; Pfefferle AD; Petrovic I; Greene SB; Perou CM; Rosen JM
    Oncogene; 2015 Dec; 34(49):5997-6006. PubMed ID: 25746005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells.
    López-Arribillaga E; Rodilla V; Colomer C; Vert A; Shelton A; Cheng JH; Yan B; Gonzalez-Perez A; Junttila MR; Iglesias M; Torres F; Albanell J; Villanueva A; Bigas A; Siebel CW; Espinosa L
    Nat Commun; 2018 Jul; 9(1):2992. PubMed ID: 30065304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch signaling as a therapeutic target for breast cancer treatment?
    Han J; Hendzel MJ; Allalunis-Turner J
    Breast Cancer Res; 2011 May; 13(3):210. PubMed ID: 21672271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-suppressive activity of Lunatic Fringe in prostate through differential modulation of Notch receptor activation.
    Zhang S; Chung WC; Wu G; Egan SE; Xu K
    Neoplasia; 2014 Feb; 16(2):158-67. PubMed ID: 24709423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CG Is a Potential Therapeutic Target in Androgen Receptor-Indifferent Metastatic Prostate Cancer.
    Chung WC; Zhou X; Atfi A; Xu K
    Am J Pathol; 2020 Nov; 190(11):2194-2202. PubMed ID: 32805234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.
    Islam SS; Mokhtari RB; Noman AS; Uddin M; Rahman MZ; Azadi MA; Zlotta A; van der Kwast T; Yeger H; Farhat WA
    Mol Carcinog; 2016 May; 55(5):537-51. PubMed ID: 25728352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.